Business
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
FOSTER CITY, Calif., April 28, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing.
About this update from Gilead Sciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1728,"height":576,"url":"https://media.zenfs.com/en/business-wire.com/460cbd18ef85ad5d4c015612436a6269"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5cnfMxmVVisQomXNoYM2qA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/460cbd18ef85ad5d4c015612436a6269","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/89bPHEjUauLAyB2mdLe8pQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA-/https://media.zenfs.com/en/business-wire.com/460cbd18ef85ad5d4c015612436a6269","width":1200,"height":400}},"lazy":false},{"type":"text","content":"FOSTER CITY, Calif., April 28, 2026--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing.","length":461,"tagName":"p"},{"type":"text","content":"The acquisition builds on Kite, a Gilead Company, and Arcellx’s successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and eliminating future profit‑share, milestone and royalty obligations, Gilead is positioned to accelerate development, streamline decision‑making and maximize the long‑term potential of the program.","length":482,"tagName":"p"},{"type":"text","content":""With the Arcellx acquisition, our focus turns to executing with speed and discipline as we prepare to bring anito‑cel to patients," said Cindy Perettie, Executive Vice President and Global Head of Kite. "I want to thank the Arcellx team for their scientific leadership, close collaboration to date and deep expertise they bring as we advance anito‑cel. With this acquisition, anito‑cel and the differentiated D‑Domain BCMA binder will advance within Kite, combining this science with our global manufacturing, regulatory and commercial capabilities to unlock the full value o...